Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 12/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532324 | 0.82 | NR4A2 (0.62) | NR4A2CREBBPAXLMAP2K1TSHR | |
| SCHEMBL2035795 | 0.77 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL3348369 | 0.73 | ATM (0.46) | TSHRKDM4EALDH1A1GLAGAA | |
| SCHEMBL1607800 | 0.71 | NR4A2 (0.62) | NR4A2CREBBPAXLMAP2K1KDM4E | |
| SCHEMBL31753965 | 0.71 | NR4A2 (0.62) | NR4A2CREBBPAXLMAP2K1KDM4E | |
| SCHEMBL27185747 | 0.70 | ATM (0.44) | TSHRKDM4EALDH1A1GLAGAA | |
| SCHEMBL16597349 | 0.70 | NR4A2 (0.49) | NR4A2CREBBPAXLMAP2K1TSHR | |
| SCHEMBL22864676 | 0.70 | NR4A2 (0.60) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL24704112 | 0.70 | MAP2K1 (0.42) | NR4A2CREBBPAXLMAP2K1TSHR | |
| SCHEMBL23148064 | 0.70 | HTR6 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885CREBBP 3960/4885AXL 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.